ICON plc | Clinical Research Organisation (CRO) for Drug Development

The key to remarkable rare disease registries

Building trust and collaboration with patient advocacy organisations

The evolution of the Pharmacovigilance System Master File

Ensuring regulatory compliance with the PSMF.

Mainstreaming Cell & Gene Therapies

Development, manufacturing, regulation and market access

The RACE for Children Act

How industry can accelerate readiness through collaboration with patient organisations.

Featured Services

Seeking parallel consultation from regulators and HTA bodies in Europe

Market Access

Expertise in mission-critical pricing, market access, and reimbursement.

Site & Patient Solutions

Transforming recruitment through patient-centric trials and real-world, real-time data.

Biotech

ICON provides full service outsourcing and flexible support for biotech specific needs such as due diligence and asset valuation.

Functional Resourcing

From recruitment of a single clinical professional to managing entire global functions.

Increasing Site and Patient Compliance

FIRECREST: Digital solutions to increase efficiency in clinical trials by driving site performance.

ICON Insights

19 September 2022

Clinical development challenges faced by advanced therapies for rare disease

Advanced therapies are a class of products based on genes, tissues or cells used to treat or deliver treatment to patients.

19 September 2022

Advanced therapies for rare disease - a regulatory roadmap

Navigating advanced therapy development for rare diseases is challenging from many perspectives and requires a customised development strategy.

12 September 2022

Diarmaid Cunningham, Chief Administrative Officer and General Counsel, reflects on the publication of ICON’s 2021 ESG report

ICON has published our 2021 ESG report, which shows the strong progress we have made against our ESG priorities and commitments.

20 July 2022

Clinical trials through a child’s eyes: Writing lay summaries for paediatric trial results

Patient centricity and transparency are increasingly important topics in the area of clinical trials. How can sponsors create a PLS that is better understandable to paediatric audiences?

14 June 2022

Using Bayesian-based, model-assisted designs to improve dose selection in early phase oncology trials

As oncology therapeutics and early phase design models evolve, sponsors will benefit from working with a partner experienced in innovative adaptive designs for phase 1 and 2 oncology trials.

08 June 2022

Interviews with patients in clinical trials

Interviewing patients in clinical trials is a valid approach to understanding the patient perspective of a disease or treatment and provides context for interpreting quantitative clinical data.

26 May 2022

Cell and Gene Therapy: Specific Market Authorisation Guidances

Therapeutic developers may benefit from working with a partner whose regulatory expertise with CGTs will help ensure that development programmes are optimal and compliant.

25 May 2022

Why ICON is celebrating its first Inclusion Day

Inclusion Day is an opportunity for us to come together in ICON as an organisation to think about the choices we make to further inclusion and diversity.

19 May 2022

Irritable Bowel Disease (IBD): A patient’s perspective

Finding appreciation in the experience and treatment of IBD as a life-changing condition.

Services

Sectors

Therapeutics

Innovation

Insights

News & Events

About ICON

Healthcare Intelligence

Environmental, Social & Governance 2021 report

Diversity, Equity and Inclusion in Rare Disease Clinical Trials: Beyond Buzzwords

Using longitudinal qualitative research to capture the patient voice